Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019158 (hepatitis)
 30,205 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

To determine whether host dependent differences modulated hepatitis delta virus replication in chronic delta hepatitis, we tested HDV RNA in homosexual and intravenous drug abuser populations. Overall, the seroprevalence of HDV RNA in the two groups with matching clinical characteristics was 72% (76/106 patient visits). A trend for greater prevalence of HDV RNA was noted at initial presentation in homosexuals (82%) compared to intravenous drug abusers (60%, P less than 0.05) and this trend appeared to be maintained during two years of sequential follow-up. The seroprevalence of co-appearing IgM and IgG anti-HD antibodies was similar in the two groups of patients. However, in HDV RNA positive homosexuals IgG anti-HD antibody was more prevalent, and additionally, assumed concordance with HDV RNA of 92% although the significance of this observation is unclear. The difference in prevalence of HIV in the two groups did not reach statistical significance. Prospective studies are required to confirm differences in HDV replication in various patient groups and to define underlying mechanisms.
 ...
PMID:Host dependent modulation of hepatitis delta virus replication in chronic delta hepatitis. 180 56

The human immunodeficiency virus (HIV-1) envelope glycoprotein gp160 was produced in large-scale microcarrier cultures of Vero cells, using a system involving coinfection with two recombinant vaccinia viruses. The immunogenicity of this material was studied in conjunction with a number of different adjuvant formulations, and chimpanzees were then immunized with gp160 in conjunction with Al(OH)3, Al(OH)3 and sodium deoxycholate, and a lipid-based adjuvant. The Al(OH)3-gp160 vaccine formulation elicited very poor immune responses in two chimpanzees, and these animals were further immunized with gp160 in conjunction with a lipid-based adjuvant. Immunization with the latter formulation lead to induction of high-titer neutralizing antibodies, and, following challenge with HIV-1, one chimpanzee demonstrated no evidence of virus infection over a period of 3 years. The second chimpanzee, which had previously been infected with non-A, non-B hepatitis, and two animals immunized with gp160 with Al(OH)3 and deoxycholate were not protected against challenge.
 ...
PMID:Characterization of a vaccinia-derived recombinant HIV-1 gp160 candidate vaccine and its immunogenicity in chimpanzees. 184 26

In a study of the content of occupational health care for hospital workers we carried out a separate study to measure the professional protection used to prevent contamination with HIV or hepatitis B virus. Therefore we carried out a study among Dutch general and orthopaedic surgeons. A questionnaire was sent to a representative sample of this population. The conclusions are that the respondents are relatively poorly informed about HIV and (or) hepatitis risks. A relatively small part of the respondents used protecting instruments; 40 (operating rooms) and 83% (emergency departments) of the respondents did not use safety glasses. The availability of protecting instruments is higher in operating rooms than in emergency departments, but this availability does not imply use of these instruments. The information on occupational contamination risks, the individual safety measures and the quality of the safety glasses are subject to criticism.
 ...
PMID:[Insufficient protection against infection with HIV in general and orthopedic surgeons]. 186 40

We undertook a prospective controlled clinical trial of 109 patients to determine whether postoperative blood salvage in patients undergoing total hip or knee arthroplasty decreased the need for transfusion with banked blood. The average amount of blood collected in our series was 493 ml, most of which was collected in the first four postoperative hours. In patients undergoing bilateral total knee arthroplasty, there was a 54% reduction in banked blood utilisation. None of our patients developed adverse effects from the reinfused material. The cost of collecting and processing wound drainage using the Haemolite cell washer was $175 per patient, regardless of the volume processed, compared to $125 for a unit of banked blood. By reducing the requirement for homologous transfusion, blood salvage diminishes the risks of transmission of HIV and hepatitis viruses. In those cases where the equivalent of two units of blood are reinfused, blood salvage saves money. However, due to the small amounts of blood collected in unilateral hip or knee arthroplasty, we do not recommend its routine application in these cases.
 ...
PMID:Postoperative blood salvage in total hip and knee arthroplasty. A randomised controlled trial. 158 Aug 99

Recombinant factor VIII is currently in the late stages of clinical trials. The available studies indicate that the product is safe and well-tolerated, and appears to be free of virus diseases such as HIV and hepatitis infections. Based on these early studies, recombinant coagulation factors appear to have enormous promise and potential for transfusion medicine. The synthesis of large quantities of safe material may lead to the development of techniques for daily administration of factor VIII aimed at the prevention of joint and soft tissue bleedings. There is also the promise of decreased costs, as techniques for the efficient synthesis of recombinant proteins are refined further.
 ...
PMID:The use of recombinant factor VIII in the management of hemophilia. 190 60

Hepatitis C virus (HCV) is the major etiologic agent associated with non-A, non-B hepatitis. This study was designed to assess virologic and serologic markers in hemophiliacs exposed to non-heat-treated and/or virus-inactivated plasma derivatives. Serial bleeds from 48 hemophilic patients were analyzed for the presence of HCV viral RNA sequences as detected by polymerase chain reaction (PCR) and antibodies to structural (core) and nonstructural (C-100 and 33C) proteins by specific dot immunoblot assay. All patients exposed to non-heat-treated products, and four of six patients exposed only to virus inactivated products, had evidence of HCV infection. However, over the 5-yr study period, six exposed patients (13%) consistently lacked detectable anti-C-100 and seven (15%) lost this antibody. HCV viremia (PCR positive) was found in 91% of exposed patients, and was significantly more frequent in HIV seropositive hemophiliacs (P less than 0.05). Six patients had high antibody level to HCV and elevated ALT, but appeared to clear viremia. Four hemophiliacs were HCV seropositive but lacked detectable viremia. These data indicate that hemophiliacs remain persistently infected by HCV and that antibody to the core antigen of HCV is a reliable marker of this transfusion transmissible agent.
 ...
PMID:Evidence for persistent hepatitis C virus (HCV) infection in hemophiliacs. 193 52

HIV transmission through sharing of drug injection paraphernalia is the single largest mode of infection in Puerto Rico. Of special concern to health professionals is the lack of information related to HIV risk behavior and lifestyles of IVDU's not in drug treatment. The paper analyzes the extent to which 862 currently active IVDU's in Puerto Rico had utilized drug treatment services and the differences between IVDU's with and without prior treatment history. Results show that two thirds of the IVDU's had been previously enrolled in drug treatment on an average of three times and a median per episode length of stay of 3 weeks. A step-wise discriminant analysis revealed that the number of years of drug injection previous incarceration, self-reported previous diagnoses of hepatitis and living with parents are relevant discriminating factors between treatment utilizers and non-utilizers. Policy implications of the results are also discussed.
 ...
PMID:HIV risk and prior drug treatment among Puerto Rican intravenous drug users. 194 23

Premofil M SRK, licensed in Switzerland by the IKS since mid-1990, was clinically tested in close collaboration with 7 hemophilia treatment centers. Up to May 1991, we collected results of in vivo recovery from 17 patients, half-life determinations from 12, and safety data from 9 who were exclusively treated with the preparation for several months. The mean in vivo recovery of factor VIII was calculated to be 77 +/- 14%; the rise in factor VIII activity in plasma following injection of one unit/kg body weight was 1.6 +/- 0.3 units/dl. The mean halflife was 11.9 +/- 4.6 hours. No side reactions were registered throughout the study period. None of the patients showed any signs of HIV or hepatitis infection. It can bei concluded that Premofil M SRK fulfills the requirements related to tolerance, efficacy and safety for a factor VIII concentrate.
 ...
PMID:[Clinical testing of Premofil M SRK, a blood coagulation factor VIII concentrate purified from human plasma using monoclonal an antibodies]. 194 60

The well-documented viral safety of albumin arises from several factors operating in concert, including virus removal during preparation, immune neutralization, serendipitous inactivation, virus sterilization through pasteurization. Safety with respect to HBV transmission was achieved even prior to the development of sensitive screening tests for HBsAg, as can be predicted given the initial virus load and the influence of factors affecting removal and inactivation. Coagulation factor concentrates, as traditionally prepared, are known to have transmitted the viral agents of hepatitis and AIDS with high frequency. Application of virucidal procedures to these concentrates, in some cases, appears to have eliminated virus transmission, raising the question as to whether absolute safety has now been achieved. Clinical proof of absolute safety is made difficult by the small number of eligible patients who can be monitored, lengthy and expensive monitoring procedures, and opportunity for transmission of virus by product-independent routes. Based on viral load analysis, modern coagulation factor concentrates are predicted to have the same probability of freedom from HIV, HBV, and HCV transmission as that exhibited by albumin.
 ...
PMID:Blood protein derivative viral safety: observations and analysis. 196 4

A multicenter study evaluated the potential for transmitting non-A/non-B hepatitis, as well as other viruses, with the use of the factor VIIIC product Monoclate. This product is purified from plasma via the monoclonal process that includes heat treatment for ultra-purification as a final step. Twenty different lots of Monoclate were used, and each patient received the assigned lot for the first 6 months of the trial. Nineteen of 38 patients adhered strictly to International Committee on Thrombosis and Hemostasis criteria in that they had normal liver enzymes, no evidence of hepatitis prestudy, and had no previous blood product use. Fourteen hemophilia centers from the United States, the United Kingdom, the Netherlands, and Israel participated in this study. Development of factor VIII inhibitor occurred in six of 38 patients, which was within the statistically expected range. Adverse events were mild, and Monoclate was well tolerated in this group. All 38 patients remained HIV seronegative.
 ...
PMID:Viral safety and inhibitor development associated with factor VIIIC ultra-purified from plasma in hemophiliacs previously unexposed to factor VIIIC concentrates. The Monoclate Study Group. 196 15


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>